Vikram Bajaj | Co- Founder, Google Life Sciences, Former CSO, GRAIL, Managing Director,
Foresite Capital Management

Vikram Bajaj, Co- Founder, Google Life Sciences, Former CSO, GRAIL, Managing Director,, Foresite Capital Management

Vik is a Managing Director at Foresite, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare. Prior to joining Foresite Capital, Vik was the Chief Scientific Officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the Co-Founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and served as Chair of its Scientific Advisory Board. A former academic principal investigator, Vik retains appointments as Associate Professor (consulting) at the Stanford School of Medicine, and as an Affiliate Scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology. Vik's research interests lie at the interface of the physical sciences, engineering, and the life sciences. He and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point-of-care testing, methods and devices that dramatically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics and integrative systems biology. Aspects of this work have been commercialized through several startups. At GRAIL, Vik led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development. He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy's LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences.

Appearances:



BioData West- NASA Ames Satellite Conference & Workshops @ 15:30

Investing in healthcare- What you need to be successful with a VC

  • What do pharmaceutical companies and VC’s want to invest in?
  • How are we seeing digital investments paying off across pharma and healthcare?
  • What factors are required to gain successful investment from pharmaceuticals?

BioData West: Day 1 @ 09:20

Where does emerging technology such as AI, precision medicine and next generation diagnostics fit into a health system- What is the value? Where is the evidence? How do you persuade us to implement?

  • Is the clinic ready for the influx of new precision medicines?
  • What are CIOs at large healthcare systems looking for to drive precision medicine into the clinic? 
  • What value has been generated to health systems through precision medicine? Are we focusing on the right priorities?

back to speakers